<DOC>
	<DOC>NCT02691182</DOC>
	<brief_summary>Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study are invited to participate in this study. This is a Phase 3 open label extension (OLE) study with the objective of collecting long-term safety data on the use of SPN-810 in treating impulsive aggression in pediatric subjects with ADHD, when taken in conjunction with standard ADHD treatment. After confirmation of eligibility, all subjects will be treated with SPN-810.Subjects will be given a choice to extend participation in this study every 6 months for up to 36 months.</brief_summary>
	<brief_title>Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<criteria>1. Healthy male or female subjects, who completed and converted from a satisfactory participation in the study 810P301or 810P302 or discontinued early from the previous study during the maintenance phase and allowed to enroll only after consultation between the Investigator, the Medical Monitor and the Sponsor. 2. Medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs). 3. Existing diagnosis of ADHD, as described by DSM5 and confirmed by the KSADS PL 2013 from study 810P301 or 810P302. 4. Currently receiving monotherapy treatment with FDAapproved ADHD medication (stimulants and nonstimulants). 5. Weight of at least 20 kg. 6. Written Informed Consent obtained from the subject's parent or LAR, and written Informed Assent obtained from the subject if appropriate. 1. Body Mass Index (BMI) in 99th percentile or above. 2. Clinically significant change in health status, safety concern or any other reason that, in the opinion of the Sponsor or the Investigator, would prevent the subject from participating in this study or successfully completing this study. 3. Pregnancy or refusal to practice contraception during the study (for female subjects of childbearing potential and sexually active males). 4. Current substance or alcohol use. 5. Suicidal thoughts or behaviors confirmed at last visit in the previous doubleblind randomized study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>